15 unknown, 14 recruiting, 12 completed, 6 terminated. 57 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 57 | Unknown 15, Recruiting 14, Completed 12, Terminated 6, Not yet recruiting 5, Enrolling by invitation 2, Active not recruiting 1, Suspended 1, Withdrawn 1 |
Follow Vasculitis: new trials by email Literature Review of Vasculitis trials Research Report on Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Non Inferiority KawasakI Trial With Anakinra Anakinra, Intravenous Immunoglobulins, Human - Kawasaki Disease, Anakinra | Phase 4 | Withdrawn | Meyer Children's Hospital IRCCS | 2026-04-01 | 2026-10-26 | |
| Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis Vanakizumab, Ivarmacitinib, Prednisone - Takayasu Arteritis (TAK) | Phase 4 | Not yet recruiting | Chinese SLE Treatment And Research Group | 180 | 2026-04-01 | 2026-03-05 |
| Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases Dengue 1,2,3,4 (attenuated) vaccine - Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA) | Phase 4 | Recruiting | University of Sao Paulo General Hospital | 477 | 2026-03-16 | 2026-07-20 |
| Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis. Rituximab - ANCA Associated Vasculitis (AAV), Polyangiitis (GPA) | Phase 4 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 70 | 2026-02-01 | 2026-03-05 |
| Effect of Pirfenidone on TA Fibrosis Pirfenidone Capsules, Placebo - Takayasu Arteritis | Phase 4 | Not yet recruiting | Shanghai Zhongshan Hospital | 92 | 2025-12-20 | 2026-01-08 |
| Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA Mepolizumab 100 MG Injection [Nucala], Mepolizumab 300 mg - EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma | Phase 4 | Enrolling by invitation | Azienda Ospedaliero Universitaria di Cagliari | 90 | 2025-10-17 | 2026-01-15 |
| SGLT-2 Inhibitors on Albuminuria in Chronic Kidney Disease Patients With Lupus Nephritis and ANCA- Associated Vasculitis Gliflozin - Lupus Nephritis (LN), ANCA Associated Vasculitis (AAV) | Phase 4 | Not yet recruiting | Federico II University | 40 | 2025-09-01 | 2025-06-25 |
| The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis Deucravacitinib, Adalimumab - Takayasu Arteritis (TAK) | Phase 4 | Not yet recruiting | Chinese SLE Treatment And Research Group | 50 | 2025-06-15 | 2025-06-10 |
| Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease Rivaroxaban Oral Tablet [Xarelto], Aspirin or Clopidogrel, Warfarin - Kawasaki Disease, Coronary Artery Aneurysm | Phase 4 | Recruiting | Children's Hospital of Fudan University | 100 | 2025-06-01 | 2026-07-06 |
| Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy? Oral prednisolone and SoC, Gut-directed budesonide and SoC, Mycophenolate mofetil (MMF) and SoC - IgA Nephropathy, Renal Insufficiency, Chronic | Phase 4 | Recruiting | Christian Medical College, Vellore, India | 585 | 2025-02-15 | 2025-07-14 |
| Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases Shingrix, vaccination with 2 doses of Shingrix vaccine - Systemic Vasculitis, Spondylarthropathies | Phase 4 | Enrolling by invitation | Region Skane | 240 | 2024-12-17 | 2025-01-10 |
| Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis Avacopan, prednisolone and rituximab, Prednisolone and rituximab - ANCA Associated Vasculitis (AAV) | Phase 4 | Recruiting | Chiba University | 160 | 2024-11-15 | 2025-05-04 |
| A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis Prednisone, Methotrexate, Tocilizumab - Takayasu Arteritis | Phase 4 | Recruiting | Shanghai Zhongshan Hospital | 124 | 2024-06-28 | 2024-10-17 |
| A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis Avacopan, Placebo, Standard of Care - Antineutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 4 | Recruiting | Amgen | 300 | 2024-02-07 | 2026-09-30 |
| Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease Rivaroxaban (Xarelto) - Kawasaki Disease, Pilot Study | Phase 4 | Recruiting | Children's Hospital of Fudan University | 10 | 2024-01-10 | 2026-10-22 |
| Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease Adult human bone marrow derived, cultured, pooled, allogeneic mesenchymal stromal cells - Critical Limb Ischemia, Buerger's Disease | Phase 4 | Recruiting | Cell Biopeutics Resources Sdn Bhd | 3 | 2024-01-01 | 2025-09-09 |
| Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM) Telitacicept, Placebo of Telitacicept - ANCA Associated Vasculitis | Phase 4 | Recruiting | Chinese SLE Treatment And Research Group | 40 | 2023-06-29 | 2023-07-27 |
| Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Recombinant Herpes Zoster Vaccine (RZV), MTX Discontinuation, MMF Discontinuation - Rheumatoid Arthritis, Spondylitis, Ankylosing | Phase 4 | Active not recruiting | University of Sao Paulo General Hospital | 2005 | 2023-05-23 | 2026-05-04 |
| Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM) Azathioprine, Telitacicept - ANCA-associated Vasculitis, Maintenance Therapy | Phase 4 | Recruiting | Chinese SLE Treatment And Research Group | 40 | 2023-03-09 | 2023-07-28 |
| Stratified Therapy on Pediatric AAGN GlucoCorticoid - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, ANCA-Associated Glomerulonephritis | Phase 4 | Unknown | Wang Mo | 200 | 2023-01-01 | 2023-08-01 |
Showing 20 of 57. Sign in to see all of them.
Granulomatosis with Polyangiitis (13) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (11) · Microscopic Polyangiitis (10) · Takayasu Arteritis (9) · Giant Cell Arteritis (6) · Mucocutaneous Lymph Node Syndrome (5) · Systemic Vasculitis (5) · Arthritis, Juvenile (4) · Arthritis, Rheumatoid (4) · Behcet Syndrome (4) · Churg-Strauss Syndrome (4) · Lupus Erythematosus, Systemic (3) · Phlebitis (3) · Polymyalgia Rheumatica (3)
Cardiovascular Diseases (57) · Vascular Diseases (57) · Skin and Connective Tissue Diseases (50) · Skin Diseases (49) · Skin Diseases, Vascular (48) · Immune System Diseases (34) · Autoimmune Diseases (32) · Systemic Vasculitis (21) · Nervous System Diseases (18) · Respiratory Tract Diseases (18) · Arteritis (17) · Lung Diseases (17) · Brain Diseases (16) · Central Nervous System Diseases (16)
Rituximab (8) · Prednisone (6) · Azathioprine (5) · Glucocorticoids (5) · Methotrexate (5) · tofacitinib (5) · Adalimumab (4) · Cyclophosphamide (4) · tocilizumab (4) · Prednisolone (3) · Aspirin (2) · Dalteparin (2) · Hydrocortisone (2) · Hydroxychloroquine (2) · Immunoglobulin G (2)
Shanghai Zhongshan Hospital (6) · Chinese SLE Treatment And Research Group (5) · Massachusetts General Hospital (3) · Assistance Publique - Hôpitaux de Paris (2) · Chiba University (2) · Children's Hospital of Fudan University (2) · Green Cross Corporation (2) · Hospices Civils de Lyon (2) · Region Skane (2) · University of Florence (2) · University of Sao Paulo General Hospital (2) · Amgen (1) · Asan Medical Center (1) · Azienda Ospedaliero Universitaria di Cagliari (1) · CSA Medical, Inc. (1)
China (14) · United States (9) · Italy (4) · Brazil (3) · Denmark (3) · France (3) · India (3) · South Korea (3) · Japan (2) · Switzerland (2) · United Kingdom (2) · Burma (1) · Czechia (1) · Finland (1) · Greece (1)
Lindi Jiang, PhD (4) · Fang Liu, MD (2) · Ana D Fernandes, MA (1) · Coen A Stegeman, MD, PhD (1) · David D'Cruz (1) · David RW Jayne, MD MRCP (1) · Farhad Shahram, Professor (1) · Filippo Festini, RN, BA, BSN (1) · Filippo Festini, RN, BSN, MSN (1) · Furen Zhang (1) · Gabriele Simonini, Prof (1) · George T John, DM, FRCP, FRACP (1)
PMID 25153486, PMID 34061144, PMID 14558057, PMID 18240234, PMID 19054820, PMID 21540203, PMID 21626222, PMID 21859696, PMID 22089462, PMID 22298793, PMID 22360152, PMID 22674883, PMID 22908326, PMID 22931582, PMID 22949223, PMID 22992045, PMID 23045170, PMID 23123020, PMID 23525305, PMID 23590801, PMID 23818263, PMID 24807875, PMID 24961747, PMID 25693055, PMID 25697557, PMID 27242368, PMID 28968874, PMID 29247107, PMID 30146446, PMID 32087733, PMID 33164993, PMID 33596356, PMID 35110332, PMID 35110333, PMID 35365179, PMID 36853224, PMID 36927642, PMID 37024906, PMID 37540159, PMID 37734880, PMID 38123922, PMID 38251564, PMID 41638742, PMID 41679320, PMID 41932224, PMID 42261247, PMID 42276802, PMID 42294825, PMID 42843284, PMID 9041949
2008 (1), 2009 (1), 2018 (1), 2023 (1), 2025 (1)